Roche chief's comments about deal discipline push shares up

Here's the latest example of parsing a pharma CEO's statements about M&A: After Roche ($RHHBY) chief Severin Schwan said over the weekend that deals have to be "worth it financially," Notenstein analysts added that to their checklist of evidence against an offer for Alexion ($ALXN). Roche shares rose after the analysts' comments went public in NZZ am Sonntag. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.